{"podcast":{"title":"Business Of Biotech","slug":"business-of-biotech-123501","podcast_index_feed_id":123501,"rss_url":"https://rss.buzzsprout.com/1011661.rss","website_url":"https://www.bioprocessonline.com/solution/the-business-of-biotech-podcast","image_url":"https://storage.buzzsprout.com/35u0bccu9j9xpr9zrrjias54otax?.jpg","author":"Ben Comer","episode_count":310,"summary":"The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.","last_synced_at":"2026-06-08T22:18:30.179389+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501"},"episode":{"title":"Radiotherapeutics For CNS Cancers With Plus Therapeutics' Marc Hedrick, M.D.","slug":"radiotherapeutics-for-cns-cancers-with-plus-therapeutics-marc-hedrick-m-d","published_at":"2026-03-16T10:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/radiotherapeutics-for-cns-cancers-with-plus-therapeutics-marc-hedrick-m-d","show_page_url":"https://stenobird.com/podcast/business-of-biotech-123501","url":"https://www.buzzsprout.com/1011661/episodes/18828654-radiotherapeutics-for-cns-cancers-with-plus-therapeutics-marc-hedrick-m-d.mp3","audio_url":"https://www.buzzsprout.com/1011661/episodes/18828654-radiotherapeutics-for-cns-cancers-with-plus-therapeutics-marc-hedrick-m-d.mp3","summary":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech we speak with Dr. Marc Hedrick, M.D., President and CEO at Plus Therapeutics, about the company's pivot from cell therapy to radiotherapeutics for brain cancers, and what's behind the choice of Rhenium-186 as the radioisotope for its lead development candidate, Reyobiq. We'll talk about Plus Therapeutics' diagnostic subsidiary, CNSide, and hear from Marc about recent FDA meetings and the ...","meta_description":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech we speak with Dr. Marc Hedrick, M.D., President a…","key_points":[],"chapters":[],"topics":[],"duration_seconds":3240,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/radiotherapeutics-for-cns-cancers-with-plus-therapeutics-marc-hedrick-m-d/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/radiotherapeutics-for-cns-cancers-with-plus-therapeutics-marc-hedrick-m-d.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}